nodes	percent_of_prediction	percent_of_DWPC	metapath
Niacin—SLC22A5—Dactinomycin—skin cancer	0.21	0.735	CbGbCtD
Niacin—CYP2D6—Vemurafenib—skin cancer	0.0755	0.265	CbGbCtD
Niacin—HCAR2—connective tissue—skin cancer	0.0132	0.101	CbGeAlD
Niacin—HCAR2—skin of body—skin cancer	0.0119	0.091	CbGeAlD
Niacin—QPRT—female reproductive system—skin cancer	0.0111	0.0848	CbGeAlD
Niacin—NNMT—nipple—skin cancer	0.0105	0.0799	CbGeAlD
Niacin—HCAR2—lymphoid tissue—skin cancer	0.00967	0.0737	CbGeAlD
Niacin—QPRT—head—skin cancer	0.0093	0.0709	CbGeAlD
Niacin—QPRT—Nicotinate metabolism—PTGS2—skin cancer	0.00901	0.0929	CbGpPWpGaD
Niacin—NNMT—connective tissue—skin cancer	0.00744	0.0567	CbGeAlD
Niacin—SLC5A8—Transport of inorganic cations/anions and amino acids/oligopeptides—SLC12A2—skin cancer	0.00741	0.0764	CbGpPWpGaD
Niacin—NNMT—mammalian vulva—skin cancer	0.00613	0.0467	CbGeAlD
Niacin—HCAR2—lymph node—skin cancer	0.00546	0.0416	CbGeAlD
Niacin—NNMT—female reproductive system—skin cancer	0.00525	0.04	CbGeAlD
Niacin—SLC16A3—epithelium—skin cancer	0.00482	0.0368	CbGeAlD
Niacin—NNMT—head—skin cancer	0.00438	0.0334	CbGeAlD
Niacin—SLC16A3—female reproductive system—skin cancer	0.00358	0.0273	CbGeAlD
Niacin—SLC5A8—SLC-mediated transmembrane transport—SLC12A2—skin cancer	0.00331	0.0342	CbGpPWpGaD
Niacin—NNMT—lymph node—skin cancer	0.00307	0.0234	CbGeAlD
Niacin—SLC16A3—head—skin cancer	0.00299	0.0228	CbGeAlD
Niacin—SLC16A1—epithelium—skin cancer	0.00293	0.0223	CbGeAlD
Niacin—SLC22A5—nipple—skin cancer	0.00249	0.0189	CbGeAlD
Niacin—HCAR3—GPCRs, Class A Rhodopsin-like—MC1R—skin cancer	0.00241	0.0248	CbGpPWpGaD
Niacin—HCAR2—GPCR ligand binding—PTCH2—skin cancer	0.00229	0.0237	CbGpPWpGaD
Niacin—HCAR2—Class A/1 (Rhodopsin-like receptors)—MC1R—skin cancer	0.00218	0.0225	CbGpPWpGaD
Niacin—SLC16A1—female reproductive system—skin cancer	0.00218	0.0166	CbGeAlD
Niacin—HCAR3—GPCR ligand binding—PTCH2—skin cancer	0.00217	0.0224	CbGpPWpGaD
Niacin—SLC16A3—lymph node—skin cancer	0.0021	0.016	CbGeAlD
Niacin—HCAR3—Class A/1 (Rhodopsin-like receptors)—MC1R—skin cancer	0.00206	0.0213	CbGpPWpGaD
Niacin—SLCO2B1—female reproductive system—skin cancer	0.00187	0.0143	CbGeAlD
Niacin—SLC16A1—head—skin cancer	0.00182	0.0139	CbGeAlD
Niacin—QPRT—Defective AMN causes hereditary megaloblastic anemia 1—PTGS2—skin cancer	0.00172	0.0178	CbGpPWpGaD
Niacin—SLC5A8—Transmembrane transport of small molecules—SLC12A2—skin cancer	0.00168	0.0174	CbGpPWpGaD
Niacin—HCAR2—GPCR ligand binding—MC1R—skin cancer	0.00166	0.0171	CbGpPWpGaD
Niacin—SLC16A3—SLC-mediated transmembrane transport—SLC12A2—skin cancer	0.00162	0.0167	CbGpPWpGaD
Niacin—SLC22A5—skin of body—skin cancer	0.00159	0.0121	CbGeAlD
Niacin—HCAR3—GPCRs, Class A Rhodopsin-like—PTGER4—skin cancer	0.00158	0.0163	CbGpPWpGaD
Niacin—HCAR3—GPCR ligand binding—MC1R—skin cancer	0.00157	0.0162	CbGpPWpGaD
Niacin—SLCO2B1—head—skin cancer	0.00156	0.0119	CbGeAlD
Niacin—HCAR2—Class A/1 (Rhodopsin-like receptors)—PTGER4—skin cancer	0.00143	0.0148	CbGpPWpGaD
Niacin—HCAR2—Signaling Pathways—RHOU—skin cancer	0.00142	0.0147	CbGpPWpGaD
Niacin—HCAR3—Class A/1 (Rhodopsin-like receptors)—PTGER4—skin cancer	0.00136	0.014	CbGpPWpGaD
Niacin—HCAR3—Signaling Pathways—RHOU—skin cancer	0.00135	0.0139	CbGpPWpGaD
Niacin—SLC16A1—lymph node—skin cancer	0.00127	0.0097	CbGeAlD
Niacin—SLC22A5—female reproductive system—skin cancer	0.00124	0.00948	CbGeAlD
Niacin—HCAR2—GPCR ligand binding—SHH—skin cancer	0.00118	0.0122	CbGpPWpGaD
Niacin—HCAR2—Signaling by GPCR—PTCH2—skin cancer	0.00118	0.0121	CbGpPWpGaD
Niacin—HCAR3—GPCR ligand binding—SHH—skin cancer	0.00112	0.0116	CbGpPWpGaD
Niacin—HCAR2—GPCR ligand binding—PTCH1—skin cancer	0.00112	0.0116	CbGpPWpGaD
Niacin—HCAR2—GPCR ligand binding—SMO—skin cancer	0.00112	0.0116	CbGpPWpGaD
Niacin—HCAR3—Signaling by GPCR—PTCH2—skin cancer	0.00112	0.0115	CbGpPWpGaD
Niacin—SLCO2B1—lymph node—skin cancer	0.0011	0.00835	CbGeAlD
Niacin—HCAR2—GPCR ligand binding—PTGER4—skin cancer	0.00109	0.0112	CbGpPWpGaD
Niacin—HCAR3—GPCR ligand binding—PTCH1—skin cancer	0.00106	0.011	CbGpPWpGaD
Niacin—HCAR3—GPCR ligand binding—SMO—skin cancer	0.00106	0.011	CbGpPWpGaD
Niacin—HCAR3—GPCR ligand binding—PTGER4—skin cancer	0.00103	0.0107	CbGpPWpGaD
Niacin—SLCO2B1—SLC-mediated transmembrane transport—SLC12A2—skin cancer	0.000983	0.0101	CbGpPWpGaD
Niacin—HCAR2—GPCR downstream signaling—MC1R—skin cancer	0.000937	0.00966	CbGpPWpGaD
Niacin—Bronchitis—Temozolomide—skin cancer	0.000909	0.00187	CcSEcCtD
Niacin—Stomatitis—Dactinomycin—skin cancer	0.000908	0.00187	CcSEcCtD
Niacin—Gastrointestinal disorder—Vemurafenib—skin cancer	0.000908	0.00187	CcSEcCtD
Niacin—Haemoglobin—Bleomycin—skin cancer	0.000902	0.00185	CcSEcCtD
Niacin—Oedema—Imiquimod—skin cancer	0.000897	0.00184	CcSEcCtD
Niacin—Haemorrhage—Bleomycin—skin cancer	0.000897	0.00184	CcSEcCtD
Niacin—QPRT—Metabolism—PLIN2—skin cancer	0.000895	0.00923	CbGpPWpGaD
Niacin—Hypoaesthesia—Bleomycin—skin cancer	0.000893	0.00184	CcSEcCtD
Niacin—Muscular weakness—Fluorouracil—skin cancer	0.000889	0.00183	CcSEcCtD
Niacin—HCAR3—GPCR downstream signaling—MC1R—skin cancer	0.000889	0.00916	CbGpPWpGaD
Niacin—Shock—Imiquimod—skin cancer	0.000883	0.00181	CcSEcCtD
Niacin—Tachycardia—Imiquimod—skin cancer	0.000876	0.0018	CcSEcCtD
Niacin—SLC16A1—SLC-mediated transmembrane transport—SLC12A2—skin cancer	0.000874	0.00901	CbGpPWpGaD
Niacin—Skin disorder—Imiquimod—skin cancer	0.000871	0.00179	CcSEcCtD
Niacin—Dysphagia—Fluorouracil—skin cancer	0.000871	0.00179	CcSEcCtD
Niacin—Erectile dysfunction—Temozolomide—skin cancer	0.000871	0.00179	CcSEcCtD
Niacin—Hyperhidrosis—Imiquimod—skin cancer	0.000867	0.00178	CcSEcCtD
Niacin—QPRT—Disease—CSPG4—skin cancer	0.000861	0.00888	CbGpPWpGaD
Niacin—Anorexia—Imiquimod—skin cancer	0.000855	0.00176	CcSEcCtD
Niacin—HCAR2—Signaling by GPCR—MC1R—skin cancer	0.000851	0.00878	CbGpPWpGaD
Niacin—Angina pectoris—Fluorouracil—skin cancer	0.000848	0.00174	CcSEcCtD
Niacin—Hepatitis—Dactinomycin—skin cancer	0.000837	0.00172	CcSEcCtD
Niacin—Flushing—Bleomycin—skin cancer	0.000833	0.00171	CcSEcCtD
Niacin—NNMT—Metabolism—PLIN2—skin cancer	0.000832	0.00858	CbGpPWpGaD
Niacin—Body temperature increased—Vemurafenib—skin cancer	0.000832	0.00171	CcSEcCtD
Niacin—SLC16A3—Transmembrane transport of small molecules—SLC12A2—skin cancer	0.000822	0.00848	CbGpPWpGaD
Niacin—Stomatitis—Temozolomide—skin cancer	0.000822	0.00169	CcSEcCtD
Niacin—Musculoskeletal discomfort—Imiquimod—skin cancer	0.000817	0.00168	CcSEcCtD
Niacin—Insomnia—Imiquimod—skin cancer	0.000811	0.00167	CcSEcCtD
Niacin—HCAR3—Signaling by GPCR—MC1R—skin cancer	0.000807	0.00832	CbGpPWpGaD
Niacin—Paraesthesia—Imiquimod—skin cancer	0.000806	0.00166	CcSEcCtD
Niacin—Chills—Bleomycin—skin cancer	0.000805	0.00166	CcSEcCtD
Niacin—CYP2D6—female reproductive system—skin cancer	0.000803	0.00612	CbGeAlD
Niacin—Dyspnoea—Imiquimod—skin cancer	0.0008	0.00164	CcSEcCtD
Niacin—Somnolence—Imiquimod—skin cancer	0.000798	0.00164	CcSEcCtD
Niacin—Alopecia—Bleomycin—skin cancer	0.000793	0.00163	CcSEcCtD
Niacin—Dyspepsia—Imiquimod—skin cancer	0.00079	0.00162	CcSEcCtD
Niacin—Erythema—Bleomycin—skin cancer	0.000781	0.00161	CcSEcCtD
Niacin—Decreased appetite—Imiquimod—skin cancer	0.00078	0.0016	CcSEcCtD
Niacin—Flushing—Dactinomycin—skin cancer	0.000776	0.0016	CcSEcCtD
Niacin—Hypersensitivity—Vemurafenib—skin cancer	0.000775	0.00159	CcSEcCtD
Niacin—Gastrointestinal disorder—Imiquimod—skin cancer	0.000774	0.00159	CcSEcCtD
Niacin—Atrial fibrillation—Docetaxel—skin cancer	0.000768	0.00158	CcSEcCtD
Niacin—Pain—Imiquimod—skin cancer	0.000767	0.00158	CcSEcCtD
Niacin—Dermatitis bullous—Docetaxel—skin cancer	0.000761	0.00156	CcSEcCtD
Niacin—Haemoglobin—Temozolomide—skin cancer	0.000761	0.00156	CcSEcCtD
Niacin—Stomatitis—Fluorouracil—skin cancer	0.000757	0.00156	CcSEcCtD
Niacin—Haemorrhage—Temozolomide—skin cancer	0.000757	0.00156	CcSEcCtD
Niacin—Hepatitis—Temozolomide—skin cancer	0.000757	0.00156	CcSEcCtD
Niacin—Asthenia—Vemurafenib—skin cancer	0.000755	0.00155	CcSEcCtD
Niacin—Hypoaesthesia—Temozolomide—skin cancer	0.000753	0.00155	CcSEcCtD
Niacin—SLC22A5—SLC-mediated transmembrane transport—SLC12A2—skin cancer	0.000751	0.00775	CbGpPWpGaD
Niacin—Chills—Dactinomycin—skin cancer	0.000751	0.00154	CcSEcCtD
Niacin—Oedema peripheral—Temozolomide—skin cancer	0.000745	0.00153	CcSEcCtD
Niacin—Pruritus—Vemurafenib—skin cancer	0.000744	0.00153	CcSEcCtD
Niacin—Alopecia—Dactinomycin—skin cancer	0.000739	0.00152	CcSEcCtD
Niacin—Gastrointestinal pain—Imiquimod—skin cancer	0.000734	0.00151	CcSEcCtD
Niacin—Visual impairment—Temozolomide—skin cancer	0.000729	0.0015	CcSEcCtD
Niacin—Erythema—Dactinomycin—skin cancer	0.000728	0.0015	CcSEcCtD
Niacin—SLC22A5—lymph node—skin cancer	0.000728	0.00554	CbGeAlD
Niacin—Gastrointestinal haemorrhage—Docetaxel—skin cancer	0.000727	0.0015	CcSEcCtD
Niacin—QPRT—Metabolism—CSPG4—skin cancer	0.000721	0.00744	CbGpPWpGaD
Niacin—Diarrhoea—Vemurafenib—skin cancer	0.00072	0.00148	CcSEcCtD
Niacin—Migraine—Docetaxel—skin cancer	0.000716	0.00147	CcSEcCtD
Niacin—Urticaria—Imiquimod—skin cancer	0.000713	0.00147	CcSEcCtD
Niacin—Abdominal pain—Imiquimod—skin cancer	0.000709	0.00146	CcSEcCtD
Niacin—Body temperature increased—Imiquimod—skin cancer	0.000709	0.00146	CcSEcCtD
Niacin—Eye disorder—Temozolomide—skin cancer	0.000707	0.00145	CcSEcCtD
Niacin—Tinnitus—Temozolomide—skin cancer	0.000706	0.00145	CcSEcCtD
Niacin—Flushing—Temozolomide—skin cancer	0.000702	0.00144	CcSEcCtD
Niacin—Haemoglobin—Fluorouracil—skin cancer	0.000701	0.00144	CcSEcCtD
Niacin—Leukopenia—Bleomycin—skin cancer	0.000699	0.00144	CcSEcCtD
Niacin—Rhinitis—Fluorouracil—skin cancer	0.000699	0.00144	CcSEcCtD
Niacin—Haemorrhage—Fluorouracil—skin cancer	0.000697	0.00143	CcSEcCtD
Niacin—Dizziness—Vemurafenib—skin cancer	0.000696	0.00143	CcSEcCtD
Niacin—HCAR2—Signaling Pathways—PTCH2—skin cancer	0.000696	0.00717	CbGpPWpGaD
Niacin—Hypoaesthesia—Fluorouracil—skin cancer	0.000694	0.00143	CcSEcCtD
Niacin—Angiopathy—Temozolomide—skin cancer	0.000687	0.00141	CcSEcCtD
Niacin—Cough—Bleomycin—skin cancer	0.000681	0.0014	CcSEcCtD
Niacin—Chills—Temozolomide—skin cancer	0.000679	0.0014	CcSEcCtD
Niacin—Liver function test abnormal—Docetaxel—skin cancer	0.000672	0.00138	CcSEcCtD
Niacin—CYP2D6—head—skin cancer	0.000671	0.00511	CbGeAlD
Niacin—NNMT—Metabolism—CSPG4—skin cancer	0.00067	0.00691	CbGpPWpGaD
Niacin—Vomiting—Vemurafenib—skin cancer	0.000669	0.00138	CcSEcCtD
Niacin—Alopecia—Temozolomide—skin cancer	0.000669	0.00137	CcSEcCtD
Niacin—Dry skin—Docetaxel—skin cancer	0.000667	0.00137	CcSEcCtD
Niacin—Myalgia—Bleomycin—skin cancer	0.000665	0.00137	CcSEcCtD
Niacin—Orthostatic hypotension—Docetaxel—skin cancer	0.000664	0.00137	CcSEcCtD
Niacin—Rash—Vemurafenib—skin cancer	0.000663	0.00136	CcSEcCtD
Niacin—Dermatitis—Vemurafenib—skin cancer	0.000663	0.00136	CcSEcCtD
Niacin—Hypersensitivity—Imiquimod—skin cancer	0.000661	0.00136	CcSEcCtD
Niacin—HCAR3—Signaling Pathways—PTCH2—skin cancer	0.000659	0.0068	CbGpPWpGaD
Niacin—Headache—Vemurafenib—skin cancer	0.000659	0.00136	CcSEcCtD
Niacin—Erythema—Temozolomide—skin cancer	0.000659	0.00135	CcSEcCtD
Niacin—Malnutrition—Temozolomide—skin cancer	0.000659	0.00135	CcSEcCtD
Niacin—Leukopenia—Dactinomycin—skin cancer	0.000652	0.00134	CcSEcCtD
Niacin—Asthenia—Imiquimod—skin cancer	0.000644	0.00132	CcSEcCtD
Niacin—Oedema—Bleomycin—skin cancer	0.000637	0.00131	CcSEcCtD
Niacin—Anaphylactic shock—Bleomycin—skin cancer	0.000637	0.00131	CcSEcCtD
Niacin—Pruritus—Imiquimod—skin cancer	0.000635	0.00131	CcSEcCtD
Niacin—Dysphagia—Docetaxel—skin cancer	0.000629	0.00129	CcSEcCtD
Niacin—Nausea—Vemurafenib—skin cancer	0.000625	0.00128	CcSEcCtD
Niacin—Arrhythmia—Fluorouracil—skin cancer	0.000623	0.00128	CcSEcCtD
Niacin—Vision blurred—Temozolomide—skin cancer	0.000621	0.00128	CcSEcCtD
Niacin—Myalgia—Dactinomycin—skin cancer	0.00062	0.00127	CcSEcCtD
Niacin—HCAR2—GPCR downstream signaling—PTGER4—skin cancer	0.000616	0.00636	CbGpPWpGaD
Niacin—Alopecia—Fluorouracil—skin cancer	0.000616	0.00127	CcSEcCtD
Niacin—Diarrhoea—Imiquimod—skin cancer	0.000614	0.00126	CcSEcCtD
Niacin—Angina pectoris—Docetaxel—skin cancer	0.000612	0.00126	CcSEcCtD
Niacin—Anorexia—Bleomycin—skin cancer	0.000608	0.00125	CcSEcCtD
Niacin—Erythema—Fluorouracil—skin cancer	0.000607	0.00125	CcSEcCtD
Niacin—HCAR2—Signaling by GPCR—SHH—skin cancer	0.000607	0.00625	CbGpPWpGaD
Niacin—Angioedema—Temozolomide—skin cancer	0.000602	0.00124	CcSEcCtD
Niacin—Hypotension—Bleomycin—skin cancer	0.000596	0.00122	CcSEcCtD
Niacin—Oedema—Dactinomycin—skin cancer	0.000594	0.00122	CcSEcCtD
Niacin—Dizziness—Imiquimod—skin cancer	0.000593	0.00122	CcSEcCtD
Niacin—Vertigo—Temozolomide—skin cancer	0.000592	0.00122	CcSEcCtD
Niacin—Leukopenia—Temozolomide—skin cancer	0.00059	0.00121	CcSEcCtD
Niacin—QPRT—Disease—SHH—skin cancer	0.000585	0.00604	CbGpPWpGaD
Niacin—QPRT—Disease—ENO2—skin cancer	0.000585	0.00604	CbGpPWpGaD
Niacin—HCAR3—GPCR downstream signaling—PTGER4—skin cancer	0.000584	0.00602	CbGpPWpGaD
Niacin—Palpitations—Temozolomide—skin cancer	0.000582	0.0012	CcSEcCtD
Niacin—Musculoskeletal discomfort—Bleomycin—skin cancer	0.000581	0.00119	CcSEcCtD
Niacin—HCAR3—Signaling by GPCR—SHH—skin cancer	0.000575	0.00593	CbGpPWpGaD
Niacin—HCAR2—Signaling by GPCR—SMO—skin cancer	0.000575	0.00593	CbGpPWpGaD
Niacin—HCAR2—Signaling by GPCR—PTCH1—skin cancer	0.000575	0.00593	CbGpPWpGaD
Niacin—Cough—Temozolomide—skin cancer	0.000575	0.00118	CcSEcCtD
Niacin—Paraesthesia—Bleomycin—skin cancer	0.000572	0.00118	CcSEcCtD
Niacin—Vision blurred—Fluorouracil—skin cancer	0.000572	0.00118	CcSEcCtD
Niacin—Vomiting—Imiquimod—skin cancer	0.00057	0.00117	CcSEcCtD
Niacin—Dyspnoea—Bleomycin—skin cancer	0.000568	0.00117	CcSEcCtD
Niacin—Anorexia—Dactinomycin—skin cancer	0.000567	0.00117	CcSEcCtD
Niacin—Rash—Imiquimod—skin cancer	0.000566	0.00116	CcSEcCtD
Niacin—Dermatitis—Imiquimod—skin cancer	0.000565	0.00116	CcSEcCtD
Niacin—Headache—Imiquimod—skin cancer	0.000562	0.00116	CcSEcCtD
Niacin—Arthralgia—Temozolomide—skin cancer	0.000561	0.00115	CcSEcCtD
Niacin—Myalgia—Temozolomide—skin cancer	0.000561	0.00115	CcSEcCtD
Niacin—HCAR2—Signaling by GPCR—PTGER4—skin cancer	0.00056	0.00577	CbGpPWpGaD
Niacin—Unspecified disorder of skin and subcutaneous tissue—Temozolomide—skin cancer	0.000557	0.00115	CcSEcCtD
Niacin—Decreased appetite—Bleomycin—skin cancer	0.000554	0.00114	CcSEcCtD
Niacin—SLC16A3—Cell surface interactions at the vascular wall—NRAS—skin cancer	0.000549	0.00566	CbGpPWpGaD
Niacin—Dry mouth—Temozolomide—skin cancer	0.000548	0.00113	CcSEcCtD
Niacin—Jaundice—Docetaxel—skin cancer	0.000546	0.00112	CcSEcCtD
Niacin—Stomatitis—Docetaxel—skin cancer	0.000546	0.00112	CcSEcCtD
Niacin—HCAR3—Signaling by GPCR—PTCH1—skin cancer	0.000545	0.00562	CbGpPWpGaD
Niacin—HCAR3—Signaling by GPCR—SMO—skin cancer	0.000545	0.00562	CbGpPWpGaD
Niacin—Pain—Bleomycin—skin cancer	0.000545	0.00112	CcSEcCtD
Niacin—Leukopenia—Fluorouracil—skin cancer	0.000543	0.00112	CcSEcCtD
Niacin—Musculoskeletal discomfort—Dactinomycin—skin cancer	0.000542	0.00111	CcSEcCtD
Niacin—Anaphylactic shock—Temozolomide—skin cancer	0.000538	0.00111	CcSEcCtD
Niacin—Oedema—Temozolomide—skin cancer	0.000538	0.00111	CcSEcCtD
Niacin—Nausea—Imiquimod—skin cancer	0.000533	0.0011	CcSEcCtD
Niacin—HCAR3—Signaling by GPCR—PTGER4—skin cancer	0.000531	0.00547	CbGpPWpGaD
Niacin—HCAR2—Signaling Pathways—GLI2—skin cancer	0.000527	0.00543	CbGpPWpGaD
Niacin—Skin disorder—Temozolomide—skin cancer	0.000522	0.00107	CcSEcCtD
Niacin—Hyperhidrosis—Temozolomide—skin cancer	0.00052	0.00107	CcSEcCtD
Niacin—Myalgia—Fluorouracil—skin cancer	0.000517	0.00106	CcSEcCtD
Niacin—Decreased appetite—Dactinomycin—skin cancer	0.000517	0.00106	CcSEcCtD
Niacin—Anorexia—Temozolomide—skin cancer	0.000512	0.00105	CcSEcCtD
Niacin—Pain—Dactinomycin—skin cancer	0.000508	0.00105	CcSEcCtD
Niacin—Urticaria—Bleomycin—skin cancer	0.000506	0.00104	CcSEcCtD
Niacin—Haemoglobin—Docetaxel—skin cancer	0.000506	0.00104	CcSEcCtD
Niacin—Rhinitis—Docetaxel—skin cancer	0.000504	0.00104	CcSEcCtD
Niacin—Body temperature increased—Bleomycin—skin cancer	0.000504	0.00104	CcSEcCtD
Niacin—Hepatitis—Docetaxel—skin cancer	0.000503	0.00103	CcSEcCtD
Niacin—Haemorrhage—Docetaxel—skin cancer	0.000503	0.00103	CcSEcCtD
Niacin—HCAR2—Signaling Pathways—MC1R—skin cancer	0.000503	0.00518	CbGpPWpGaD
Niacin—Hypoaesthesia—Docetaxel—skin cancer	0.000501	0.00103	CcSEcCtD
Niacin—SLCO2B1—Transmembrane transport of small molecules—SLC12A2—skin cancer	0.0005	0.00515	CbGpPWpGaD
Niacin—HCAR3—Signaling Pathways—GLI2—skin cancer	0.0005	0.00515	CbGpPWpGaD
Niacin—Oedema peripheral—Docetaxel—skin cancer	0.000496	0.00102	CcSEcCtD
Niacin—HCAR2—Signaling Pathways—GLI1—skin cancer	0.000496	0.00511	CbGpPWpGaD
Niacin—Anaphylactic shock—Fluorouracil—skin cancer	0.000495	0.00102	CcSEcCtD
Niacin—Oedema—Fluorouracil—skin cancer	0.000495	0.00102	CcSEcCtD
Niacin—QPRT—Metabolism—ENO2—skin cancer	0.00049	0.00505	CbGpPWpGaD
Niacin—Musculoskeletal discomfort—Temozolomide—skin cancer	0.00049	0.00101	CcSEcCtD
Niacin—Insomnia—Temozolomide—skin cancer	0.000486	0.001	CcSEcCtD
Niacin—Gastrointestinal pain—Dactinomycin—skin cancer	0.000486	0.000999	CcSEcCtD
Niacin—Visual impairment—Docetaxel—skin cancer	0.000485	0.000997	CcSEcCtD
Niacin—Tachycardia—Fluorouracil—skin cancer	0.000483	0.000994	CcSEcCtD
Niacin—Paraesthesia—Temozolomide—skin cancer	0.000483	0.000993	CcSEcCtD
Niacin—Dyspnoea—Temozolomide—skin cancer	0.000479	0.000986	CcSEcCtD
Niacin—Somnolence—Temozolomide—skin cancer	0.000478	0.000983	CcSEcCtD
Niacin—QPRT—Disease—FOXO4—skin cancer	0.000477	0.00492	CbGpPWpGaD
Niacin—HCAR3—Signaling Pathways—MC1R—skin cancer	0.000477	0.00492	CbGpPWpGaD
Niacin—Dyspepsia—Temozolomide—skin cancer	0.000473	0.000973	CcSEcCtD
Niacin—SLC16A3—Cell surface interactions at the vascular wall—KRAS—skin cancer	0.000472	0.00487	CbGpPWpGaD
Niacin—Anorexia—Fluorouracil—skin cancer	0.000472	0.000971	CcSEcCtD
Niacin—Eye disorder—Docetaxel—skin cancer	0.00047	0.000967	CcSEcCtD
Niacin—Abdominal pain—Dactinomycin—skin cancer	0.00047	0.000966	CcSEcCtD
Niacin—Body temperature increased—Dactinomycin—skin cancer	0.00047	0.000966	CcSEcCtD
Niacin—HCAR3—Signaling Pathways—GLI1—skin cancer	0.00047	0.00484	CbGpPWpGaD
Niacin—HCAR2—Signaling Pathways—SUFU—skin cancer	0.00047	0.00484	CbGpPWpGaD
Niacin—Hypersensitivity—Bleomycin—skin cancer	0.00047	0.000966	CcSEcCtD
Niacin—Decreased appetite—Temozolomide—skin cancer	0.000467	0.000961	CcSEcCtD
Niacin—Flushing—Docetaxel—skin cancer	0.000467	0.00096	CcSEcCtD
Niacin—Gastrointestinal disorder—Temozolomide—skin cancer	0.000464	0.000954	CcSEcCtD
Niacin—Hypotension—Fluorouracil—skin cancer	0.000463	0.000952	CcSEcCtD
Niacin—Pain—Temozolomide—skin cancer	0.00046	0.000945	CcSEcCtD
Niacin—Asthenia—Bleomycin—skin cancer	0.000457	0.00094	CcSEcCtD
Niacin—Angiopathy—Docetaxel—skin cancer	0.000457	0.000939	CcSEcCtD
Niacin—NNMT—Metabolism—ENO2—skin cancer	0.000456	0.0047	CbGpPWpGaD
Niacin—Chills—Docetaxel—skin cancer	0.000452	0.000928	CcSEcCtD
Niacin—Musculoskeletal discomfort—Fluorouracil—skin cancer	0.000451	0.000928	CcSEcCtD
Niacin—Pruritus—Bleomycin—skin cancer	0.000451	0.000927	CcSEcCtD
Niacin—Arrhythmia—Docetaxel—skin cancer	0.00045	0.000924	CcSEcCtD
Niacin—Insomnia—Fluorouracil—skin cancer	0.000448	0.000921	CcSEcCtD
Niacin—HCAR3—Signaling Pathways—SUFU—skin cancer	0.000445	0.00459	CbGpPWpGaD
Niacin—Paraesthesia—Fluorouracil—skin cancer	0.000445	0.000915	CcSEcCtD
Niacin—Alopecia—Docetaxel—skin cancer	0.000445	0.000914	CcSEcCtD
Niacin—SLC16A1—Transmembrane transport of small molecules—SLC12A2—skin cancer	0.000444	0.00458	CbGpPWpGaD
Niacin—Dyspnoea—Fluorouracil—skin cancer	0.000442	0.000908	CcSEcCtD
Niacin—Somnolence—Fluorouracil—skin cancer	0.00044	0.000905	CcSEcCtD
Niacin—Gastrointestinal pain—Temozolomide—skin cancer	0.00044	0.000904	CcSEcCtD
Niacin—Erythema—Docetaxel—skin cancer	0.000438	0.000901	CcSEcCtD
Niacin—Malnutrition—Docetaxel—skin cancer	0.000438	0.000901	CcSEcCtD
Niacin—Hypersensitivity—Dactinomycin—skin cancer	0.000438	0.0009	CcSEcCtD
Niacin—Dyspepsia—Fluorouracil—skin cancer	0.000436	0.000897	CcSEcCtD
Niacin—Decreased appetite—Fluorouracil—skin cancer	0.000431	0.000885	CcSEcCtD
Niacin—Gastrointestinal disorder—Fluorouracil—skin cancer	0.000428	0.000879	CcSEcCtD
Niacin—Urticaria—Temozolomide—skin cancer	0.000427	0.000878	CcSEcCtD
Niacin—Asthenia—Dactinomycin—skin cancer	0.000426	0.000877	CcSEcCtD
Niacin—Abdominal pain—Temozolomide—skin cancer	0.000425	0.000874	CcSEcCtD
Niacin—Body temperature increased—Temozolomide—skin cancer	0.000425	0.000874	CcSEcCtD
Niacin—Pain—Fluorouracil—skin cancer	0.000424	0.000871	CcSEcCtD
Niacin—Muscle spasms—Docetaxel—skin cancer	0.000421	0.000866	CcSEcCtD
Niacin—Diarrhoea—Dactinomycin—skin cancer	0.000407	0.000836	CcSEcCtD
Niacin—SLC16A3—Metabolism—PLIN2—skin cancer	0.000406	0.00419	CbGpPWpGaD
Niacin—Vomiting—Bleomycin—skin cancer	0.000405	0.000833	CcSEcCtD
Niacin—Rash—Bleomycin—skin cancer	0.000402	0.000826	CcSEcCtD
Niacin—Dermatitis—Bleomycin—skin cancer	0.000401	0.000826	CcSEcCtD
Niacin—SLC16A3—Cell surface interactions at the vascular wall—HRAS—skin cancer	0.000401	0.00414	CbGpPWpGaD
Niacin—Hypersensitivity—Temozolomide—skin cancer	0.000396	0.000814	CcSEcCtD
Niacin—Urticaria—Fluorouracil—skin cancer	0.000394	0.000809	CcSEcCtD
Niacin—Syncope—Docetaxel—skin cancer	0.000393	0.000808	CcSEcCtD
Niacin—Leukopenia—Docetaxel—skin cancer	0.000392	0.000806	CcSEcCtD
Niacin—Body temperature increased—Fluorouracil—skin cancer	0.000392	0.000805	CcSEcCtD
Niacin—Palpitations—Docetaxel—skin cancer	0.000387	0.000796	CcSEcCtD
Niacin—Asthenia—Temozolomide—skin cancer	0.000386	0.000793	CcSEcCtD
Niacin—Loss of consciousness—Docetaxel—skin cancer	0.000385	0.000792	CcSEcCtD
Niacin—Cough—Docetaxel—skin cancer	0.000382	0.000786	CcSEcCtD
Niacin—SLC22A5—Transmembrane transport of small molecules—SLC12A2—skin cancer	0.000382	0.00394	CbGpPWpGaD
Niacin—Pruritus—Temozolomide—skin cancer	0.00038	0.000782	CcSEcCtD
Niacin—Nausea—Bleomycin—skin cancer	0.000379	0.000778	CcSEcCtD
Niacin—Vomiting—Dactinomycin—skin cancer	0.000378	0.000777	CcSEcCtD
Niacin—Rash—Dactinomycin—skin cancer	0.000375	0.000771	CcSEcCtD
Niacin—Myalgia—Docetaxel—skin cancer	0.000373	0.000767	CcSEcCtD
Niacin—Arthralgia—Docetaxel—skin cancer	0.000373	0.000767	CcSEcCtD
Niacin—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—skin cancer	0.00037	0.000762	CcSEcCtD
Niacin—Diarrhoea—Temozolomide—skin cancer	0.000368	0.000756	CcSEcCtD
Niacin—Hypersensitivity—Fluorouracil—skin cancer	0.000365	0.00075	CcSEcCtD
Niacin—Dry mouth—Docetaxel—skin cancer	0.000365	0.00075	CcSEcCtD
Niacin—HCAR2—Signaling Pathways—SHH—skin cancer	0.000358	0.00369	CbGpPWpGaD
Niacin—Oedema—Docetaxel—skin cancer	0.000358	0.000735	CcSEcCtD
Niacin—Anaphylactic shock—Docetaxel—skin cancer	0.000358	0.000735	CcSEcCtD
Niacin—HCAR2—Signaling Pathways—RASA1—skin cancer	0.000356	0.00367	CbGpPWpGaD
Niacin—Dizziness—Temozolomide—skin cancer	0.000356	0.000731	CcSEcCtD
Niacin—Nausea—Dactinomycin—skin cancer	0.000353	0.000726	CcSEcCtD
Niacin—Shock—Docetaxel—skin cancer	0.000352	0.000723	CcSEcCtD
Niacin—Pruritus—Fluorouracil—skin cancer	0.00035	0.000721	CcSEcCtD
Niacin—Tachycardia—Docetaxel—skin cancer	0.000349	0.000717	CcSEcCtD
Niacin—Skin disorder—Docetaxel—skin cancer	0.000347	0.000714	CcSEcCtD
Niacin—Vomiting—Temozolomide—skin cancer	0.000342	0.000703	CcSEcCtD
Niacin—Anorexia—Docetaxel—skin cancer	0.000341	0.000701	CcSEcCtD
Niacin—QPRT—Disease—ERCC2—skin cancer	0.00034	0.00351	CbGpPWpGaD
Niacin—HCAR3—Signaling Pathways—SHH—skin cancer	0.00034	0.0035	CbGpPWpGaD
Niacin—HCAR2—Signaling Pathways—PTCH1—skin cancer	0.00034	0.0035	CbGpPWpGaD
Niacin—HCAR2—Signaling Pathways—SMO—skin cancer	0.00034	0.0035	CbGpPWpGaD
Niacin—Rash—Temozolomide—skin cancer	0.000339	0.000697	CcSEcCtD
Niacin—Diarrhoea—Fluorouracil—skin cancer	0.000339	0.000697	CcSEcCtD
Niacin—Dermatitis—Temozolomide—skin cancer	0.000339	0.000696	CcSEcCtD
Niacin—HCAR3—Signaling Pathways—RASA1—skin cancer	0.000338	0.00348	CbGpPWpGaD
Niacin—Headache—Temozolomide—skin cancer	0.000337	0.000693	CcSEcCtD
Niacin—Hypotension—Docetaxel—skin cancer	0.000334	0.000687	CcSEcCtD
Niacin—HCAR2—Signaling Pathways—PTGER4—skin cancer	0.000331	0.00341	CbGpPWpGaD
Niacin—Dizziness—Fluorouracil—skin cancer	0.000328	0.000674	CcSEcCtD
Niacin—SLC16A3—Metabolism—CSPG4—skin cancer	0.000327	0.00338	CbGpPWpGaD
Niacin—Musculoskeletal discomfort—Docetaxel—skin cancer	0.000326	0.00067	CcSEcCtD
Niacin—Insomnia—Docetaxel—skin cancer	0.000323	0.000665	CcSEcCtD
Niacin—HCAR3—Signaling Pathways—PTCH1—skin cancer	0.000322	0.00332	CbGpPWpGaD
Niacin—HCAR3—Signaling Pathways—SMO—skin cancer	0.000322	0.00332	CbGpPWpGaD
Niacin—Paraesthesia—Docetaxel—skin cancer	0.000321	0.00066	CcSEcCtD
Niacin—Nausea—Temozolomide—skin cancer	0.000319	0.000657	CcSEcCtD
Niacin—Dyspnoea—Docetaxel—skin cancer	0.000319	0.000655	CcSEcCtD
Niacin—QPRT—Disease—TERT—skin cancer	0.000319	0.00329	CbGpPWpGaD
Niacin—Somnolence—Docetaxel—skin cancer	0.000318	0.000654	CcSEcCtD
Niacin—Vomiting—Fluorouracil—skin cancer	0.000315	0.000648	CcSEcCtD
Niacin—Dyspepsia—Docetaxel—skin cancer	0.000315	0.000647	CcSEcCtD
Niacin—HCAR3—Signaling Pathways—PTGER4—skin cancer	0.000313	0.00323	CbGpPWpGaD
Niacin—Rash—Fluorouracil—skin cancer	0.000312	0.000642	CcSEcCtD
Niacin—Dermatitis—Fluorouracil—skin cancer	0.000312	0.000642	CcSEcCtD
Niacin—Decreased appetite—Docetaxel—skin cancer	0.000311	0.000639	CcSEcCtD
Niacin—Headache—Fluorouracil—skin cancer	0.00031	0.000638	CcSEcCtD
Niacin—Gastrointestinal disorder—Docetaxel—skin cancer	0.000309	0.000635	CcSEcCtD
Niacin—Pain—Docetaxel—skin cancer	0.000306	0.000629	CcSEcCtD
Niacin—SLC16A1—Cell surface interactions at the vascular wall—NRAS—skin cancer	0.000296	0.00305	CbGpPWpGaD
Niacin—Nausea—Fluorouracil—skin cancer	0.000294	0.000605	CcSEcCtD
Niacin—Gastrointestinal pain—Docetaxel—skin cancer	0.000292	0.000601	CcSEcCtD
Niacin—HCAR2—Signaling Pathways—FOXO4—skin cancer	0.000292	0.00301	CbGpPWpGaD
Niacin—QPRT—Metabolism—ERCC2—skin cancer	0.000285	0.00294	CbGpPWpGaD
Niacin—Body temperature increased—Docetaxel—skin cancer	0.000283	0.000581	CcSEcCtD
Niacin—Abdominal pain—Docetaxel—skin cancer	0.000283	0.000581	CcSEcCtD
Niacin—HCAR3—Signaling Pathways—FOXO4—skin cancer	0.000277	0.00285	CbGpPWpGaD
Niacin—NNMT—Metabolism—ERCC2—skin cancer	0.000265	0.00273	CbGpPWpGaD
Niacin—Hypersensitivity—Docetaxel—skin cancer	0.000263	0.000542	CcSEcCtD
Niacin—Asthenia—Docetaxel—skin cancer	0.000257	0.000527	CcSEcCtD
Niacin—SLC16A1—Cell surface interactions at the vascular wall—KRAS—skin cancer	0.000255	0.00263	CbGpPWpGaD
Niacin—Pruritus—Docetaxel—skin cancer	0.000253	0.00052	CcSEcCtD
Niacin—QPRT—Disease—BRAF—skin cancer	0.000252	0.0026	CbGpPWpGaD
Niacin—Diarrhoea—Docetaxel—skin cancer	0.000245	0.000503	CcSEcCtD
Niacin—Dizziness—Docetaxel—skin cancer	0.000236	0.000486	CcSEcCtD
Niacin—Vomiting—Docetaxel—skin cancer	0.000227	0.000467	CcSEcCtD
Niacin—Rash—Docetaxel—skin cancer	0.000225	0.000464	CcSEcCtD
Niacin—Dermatitis—Docetaxel—skin cancer	0.000225	0.000463	CcSEcCtD
Niacin—Headache—Docetaxel—skin cancer	0.000224	0.000461	CcSEcCtD
Niacin—SLC16A3—Metabolism—ENO2—skin cancer	0.000223	0.00229	CbGpPWpGaD
Niacin—SLC16A1—Metabolism—PLIN2—skin cancer	0.000219	0.00226	CbGpPWpGaD
Niacin—SLC16A1—Cell surface interactions at the vascular wall—HRAS—skin cancer	0.000217	0.00223	CbGpPWpGaD
Niacin—Nausea—Docetaxel—skin cancer	0.000212	0.000437	CcSEcCtD
Niacin—QPRT—Disease—PTGS2—skin cancer	0.000204	0.0021	CbGpPWpGaD
Niacin—HCAR2—Signaling Pathways—TERT—skin cancer	0.000195	0.00201	CbGpPWpGaD
Niacin—HCAR3—Signaling Pathways—TERT—skin cancer	0.000185	0.00191	CbGpPWpGaD
Niacin—SLC16A1—Metabolism—CSPG4—skin cancer	0.000177	0.00182	CbGpPWpGaD
Niacin—QPRT—Metabolism—PTGS2—skin cancer	0.000171	0.00176	CbGpPWpGaD
Niacin—HCAR2—Signaling by GPCR—NRAS—skin cancer	0.000164	0.00169	CbGpPWpGaD
Niacin—NNMT—Metabolism—PTGS2—skin cancer	0.000159	0.00164	CbGpPWpGaD
Niacin—QPRT—Disease—NRAS—skin cancer	0.000159	0.00164	CbGpPWpGaD
Niacin—HCAR3—Signaling by GPCR—NRAS—skin cancer	0.000156	0.00161	CbGpPWpGaD
Niacin—HCAR2—Signaling Pathways—BRAF—skin cancer	0.000155	0.00159	CbGpPWpGaD
Niacin—SLC16A3—Hemostasis—NRAS—skin cancer	0.000149	0.00153	CbGpPWpGaD
Niacin—HCAR3—Signaling Pathways—BRAF—skin cancer	0.000146	0.00151	CbGpPWpGaD
Niacin—HCAR2—Signaling by GPCR—KRAS—skin cancer	0.000141	0.00146	CbGpPWpGaD
Niacin—QPRT—Disease—KRAS—skin cancer	0.000137	0.00141	CbGpPWpGaD
Niacin—HCAR3—Signaling by GPCR—KRAS—skin cancer	0.000134	0.00138	CbGpPWpGaD
Niacin—SLC16A3—Metabolism—ERCC2—skin cancer	0.000129	0.00133	CbGpPWpGaD
Niacin—SLC16A3—Hemostasis—KRAS—skin cancer	0.000128	0.00132	CbGpPWpGaD
Niacin—HCAR2—Signaling by GPCR—HRAS—skin cancer	0.00012	0.00124	CbGpPWpGaD
Niacin—SLC16A1—Metabolism—ENO2—skin cancer	0.00012	0.00124	CbGpPWpGaD
Niacin—QPRT—Disease—HRAS—skin cancer	0.000116	0.0012	CbGpPWpGaD
Niacin—HCAR2—Signaling by GPCR—IL6—skin cancer	0.000115	0.00119	CbGpPWpGaD
Niacin—HCAR3—Signaling by GPCR—HRAS—skin cancer	0.000114	0.00118	CbGpPWpGaD
Niacin—SLC16A3—Hemostasis—TP53—skin cancer	0.000114	0.00117	CbGpPWpGaD
Niacin—QPRT—Disease—IL6—skin cancer	0.000111	0.00115	CbGpPWpGaD
Niacin—HCAR3—Signaling by GPCR—IL6—skin cancer	0.000109	0.00112	CbGpPWpGaD
Niacin—SLC16A3—Hemostasis—HRAS—skin cancer	0.000109	0.00112	CbGpPWpGaD
Niacin—HCAR2—Signaling Pathways—NRAS—skin cancer	9.71e-05	0.001	CbGpPWpGaD
Niacin—HCAR3—Signaling Pathways—NRAS—skin cancer	9.2e-05	0.000949	CbGpPWpGaD
Niacin—HCAR2—Signaling Pathways—KRAS—skin cancer	8.36e-05	0.000862	CbGpPWpGaD
Niacin—SLC16A1—Hemostasis—NRAS—skin cancer	8.03e-05	0.000828	CbGpPWpGaD
Niacin—HCAR3—Signaling Pathways—KRAS—skin cancer	7.92e-05	0.000817	CbGpPWpGaD
Niacin—SLC16A3—Metabolism—PTGS2—skin cancer	7.75e-05	0.000799	CbGpPWpGaD
Niacin—HCAR2—Signaling Pathways—TP53—skin cancer	7.43e-05	0.000766	CbGpPWpGaD
Niacin—HCAR2—Signaling Pathways—HRAS—skin cancer	7.1e-05	0.000732	CbGpPWpGaD
Niacin—HCAR3—Signaling Pathways—TP53—skin cancer	7.04e-05	0.000726	CbGpPWpGaD
Niacin—SLC16A1—Metabolism—ERCC2—skin cancer	6.98e-05	0.00072	CbGpPWpGaD
Niacin—SLC16A1—Hemostasis—KRAS—skin cancer	6.91e-05	0.000713	CbGpPWpGaD
Niacin—HCAR2—Signaling Pathways—IL6—skin cancer	6.8e-05	0.000701	CbGpPWpGaD
Niacin—HCAR3—Signaling Pathways—HRAS—skin cancer	6.73e-05	0.000694	CbGpPWpGaD
Niacin—HCAR3—Signaling Pathways—IL6—skin cancer	6.45e-05	0.000665	CbGpPWpGaD
Niacin—SLC16A1—Hemostasis—TP53—skin cancer	6.15e-05	0.000634	CbGpPWpGaD
Niacin—CYP2D6—Metabolism—PLIN2—skin cancer	6.11e-05	0.00063	CbGpPWpGaD
Niacin—SLC16A1—Hemostasis—HRAS—skin cancer	5.88e-05	0.000606	CbGpPWpGaD
Niacin—CYP2D6—Metabolism—CSPG4—skin cancer	4.93e-05	0.000508	CbGpPWpGaD
Niacin—SLC16A1—Metabolism—PTGS2—skin cancer	4.19e-05	0.000432	CbGpPWpGaD
Niacin—CYP2D6—Metabolism—ENO2—skin cancer	3.35e-05	0.000345	CbGpPWpGaD
Niacin—CYP2D6—Metabolism—ERCC2—skin cancer	1.94e-05	0.000201	CbGpPWpGaD
Niacin—CYP2D6—Metabolism—PTGS2—skin cancer	1.17e-05	0.00012	CbGpPWpGaD
